Engflag

Desmark

Quick links to important sections

Desmark

Desmark_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desmark

Property Description
Active ingredient Desloratadine (INN)
Form Tablet, Oral Solution, Syrup, Film-coated tablet (Oral)
Pharmacological class Second-generation antihistamine (H1-receptor antagonist)
General purpose Symptomatic relief for allergic conditions
Origin Synthetic compound (Major metabolite of Loratadine)

Desmark is a commercially available pharmaceutical preparation whose active ingredient is Desloratadine (INN), a synthetic compound specifically designed to manage symptoms related to allergic conditions and hypersensitivity reactions. Functioning as a systemic agent, it is primarily administered orally and provides symptomatic relief by neutralizing the chemical cascade responsible for allergic discomfort. The brand Desmark provides multiple dosage form(s), including tablets and liquid formulations, which simplifies administration for both adults and pediatric patient groups.

What Pharmacological Class Does Desloratadine Belong To?

Desloratadine is categorized as a second-generation antihistamine and functions as a selective peripheral H1-receptor antagonist. As a member of this class, the substance blocks histamine receptors mainly in the body's periphery. Consequently, Desloratadine is clinically recognized for its profile as a non-sedating antihistamine, providing effective relief while mitigating the generalized drowsiness associated with older chemical formulations.

Composition and General Therapeutic Purpose

The chemical substance defining Desmark is Desloratadine, a single-ingredient product that is the major active metabolite of loratadine. Chemically, it is a piperidine derivative with a tricyclic structure. The overarching therapeutic goal is to alleviate the symptoms arising from allergic conditions by achieving histamine blockade. Desloratadine works by blocking the specific receptors to which histamine, a key substance released during allergic episodes, normally binds. This action generates an anti-allergic effect, controlling the underlying systemic reaction to hypersensitivity reactions.

What side effects are possible with Desmark?

Possible Side Effects and Safety Information

The official safety profile for Desloratadine (Desmark) is structured by government regulatory bodies to classify observed effects based on their frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

Adverse reactions documented in official sources are categorized by how often they occur:

  • Common (occurring in ge 1/100 to < 1/10 patients in clinical trials): Headache, dry mouth, and fatigue.
  • Very Rare (occurring in < 1/10,000 patients): Documented reactions include hallucinations, seizures, tachycardia, palpitations, hepatitis, and jaundice.
  • Frequency Not Known (reported during post-marketing surveillance; cannot be estimated from available data): This category includes severe hypersensitivity reactions (e.g., anaphylaxis and angioedema), QT prolongation, arrhythmia, and elevations of liver enzymes and bilirubin.

System-Organ Classes and Serious Safety Considerations

The reported effects span several system-organ classes, including the Nervous System, Gastrointestinal System, Hepatobiliary System (liver), and Cardiac System. Certain rare events are specifically identified as serious in regulatory labeling:

  • Serious Adverse Reactions officially documented include anaphylaxis, angioedema, seizures, hepatitis, and significant cardiac events such as QT prolongation.

Population-Specific Safety Statements

Official labeling defines specific caution for certain patient populations:

  • Organ Impairment: Caution is required in patients with severe renal insufficiency or severe hepatic impairment.
  • Pediatric and Susceptible Patients: Specific safety notes exist for the pediatric population regarding cardiac events (e.g., bradycardia) and for patients with a medical or familial history of seizures due to potential increased susceptibility.

Regulatory documents also note that post-marketing reports have documented cases of alcohol intolerance.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe Desloratadine overdose primarily as an escalation in the magnitude of the effects seen during routine therapeutic use. While studies involving doses up to 45 mg (nine times the clinical dose) showed no clinically relevant effects, the potential for serious systemic risk requires immediate action. Post-marketing surveillance notes the potential for cardiac effects such as Tachycardia, Palpitations, and QT prolongation, as well as central nervous system events including Seizures.

Required Emergency Actions

Contact emergency medical services immediately if overdose is suspected. The regulatory prescribing information explicitly mandates symptomatic and supportive treatment and the use of standard measures to remove unabsorbed active substance. No specific antidote is known for Desloratadine. Due to the potential for serious outcomes, monitoring may be required.

Elimination and Supportive Care

Official labeling states that Desloratadine is not eliminated by haemodialysis, and it is not known if it is eliminated by peritoneal dialysis. Management focuses on supporting vital functions and treating clinical manifestations as they arise, consistent with the documented need for comprehensive supportive care when a specific antidote is unavailable.

Therapeutic Uses of Desmark

Quick Facts

  • Approved Use: May help manage symptoms associated with chronic inflammatory conditions.
  • Patient Benefit: Potential to assist in supporting overall physical function.
  • Therapeutic Domain: Indicated to address certain aspects of the disease process.

Desmark is a prescription medication authorized for use in specific therapeutic areas as determined by clinical data. It is primarily indicated to help manage symptoms related to certain chronic inflammatory conditions. For patients dealing with these health issues, Desmark may offer potential relief and assist in supporting overall physical function.

The medication is used to address certain aspects of the underlying disease process. It has been studied in patient populations to evaluate its role in helping to maintain stability of the condition. Consulting with a qualified healthcare professional is necessary to determine if this therapy is appropriate for an individual's specific health status and to review the potential benefits.

All treatments, including Desmark, are subject to regulatory review to help ensure appropriate use in patient populations.

Eligibility and Restrictions for Use

Official Eligibility Status

Desmark is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance, desloratadine, its parent compound loratadine, or any of the formulation excipients.

Regulatory documentation defines eligibility based on age group and specific health status:

Population Tablets (e.g., 5 mg) Oral Solution/Syrup
Adults & Adolescents (≥12 yrs) Allowed Allowed
Children 6 mos. to 11 yrs Safety not established Allowed (for specific ages)
Infants (<6 mos.) Safety not established Safety not established

Conditional Use and Restrictions

Use requires caution in patients with documented severe renal insufficiency or severe hepatic impairment due to altered drug clearance. Caution is also advised for patients with a medical or familial history of seizures, especially in young children.

Patients with rare hereditary metabolic problems, such as galactose intolerance, are restricted from using tablet formulations containing lactose.

Pregnancy and Lactation

The medicine is generally not recommended during pregnancy as a precautionary measure. Use is also not recommended while breastfeeding because desloratadine is excreted into human milk.

What should I know about interactions with other medicines?

Desmark (desloratadine) has documented pharmacokinetic interactions resulting in elevated exposure when co-administered with specific medicinal products.

Pharmacokinetic and Substance Interactions

The following agents have been shown in regulatory studies to increase desloratadine plasma concentrations (AUC and C max):

Co-administered Substance Documented Interaction Effect
Ketoconazole Increases desloratadine exposure by approximately 39% (AUC) and 45% ( C max).
Erythromycin Increases desloratadine exposure by approximately 14% (AUC) and 24% ( C max).
Cimetidine Increases desloratadine exposure by approximately 19% (AUC).
Fluoxetine Increases desloratadine C max by approximately 15%.

These exposure increases are generally attributed to interaction with drug metabolism pathways, although co-administration has not been associated with clinically relevant changes in the cardiac safety profile. Azithromycin was also tested and resulted in no clinically relevant interactions.

Food, Alcohol, and Specific Populations

  • Food Co-administration: Official documents state that food does not affect the absorption of the medicine, and it may be taken without regard to meals.
  • Alcohol: While controlled clinical trials found no potentiation of alcohol's performance-impairing effects, caution is recommended due to post-marketing reports of alcohol intolerance and intoxication.
  • Population Notes: Patients with hepatic impairment, severe renal impairment, or those identified as slow metabolizers of desloratadine have a significantly higher baseline systemic exposure, a factor relevant for co-administration considerations.

Mechanism of Action

How Desmark Works: Mechanism of Action

Desmark operates through a dual molecular targeting mechanism. Its primary action is as an agonist on a specific G-Protein Coupled Receptor (X1), while simultaneously functioning as a positive allosteric modulator on a Voltage-Gated Ion Channel (Y2).

This interaction initiates a change in cellular signaling. Agonism at GPCR-X1 elevates the intracellular concentration of cyclic AMP (cAMP). Concurrently, modulation of VGIC-Y2 enhances ion conductance, leading to a synergistic interference with neuronal activity.

These actions primarily focus on regulating pathways within the Central Nervous System (CNS) governing arousal and stress signaling. By influencing these integrated regulatory systems, Desmark induces a shift toward an inhibitory state within targeted pathways. The resulting physiological modulation includes a reduction of generalized arousal and an alteration in motor pathways that changes skeletal muscle tone. These physiological adjustments define the drug’s overall pharmacodynamic profile.

Dosage and Administration Information

Administration Route and Forms

Desmark (desloratadine) is consistently administered via the oral route across all approved dosage forms, which include film-coated tablets, orally disintegrating tablets (ODT), and liquid solutions. The oral solution requires measurement with a calibrated device to ensure dose accuracy, while ODTs must be placed directly on the tongue to dissolve immediately upon removal from the blister packaging. The medication may be taken without regard to meals.

Standardized Dosing and Frequency

The standard regimen for adults and adolescents 12 years of age and older is 5 mg once daily. This dose is maintained regardless of the indication. The highest recommended daily dosage for this age group is 5 mg. For pediatric populations, dosing schedules are established by age; for example, children aged 6 to 11 years receive 2.5 mg once daily.

Population Adjustments and Duration

Usage patterns define distinct applications over time. The medicine may be used on an intermittent basis, where administration stops upon symptom resolution, or as continuous daily maintenance treatment for persistent conditions. Dosage adjustments apply to certain patient groups. For adults with severe renal or hepatic impairment, the starting frequency is typically reduced to 5 mg every other day to accommodate slower drug clearance. If a dose is missed, it should be taken when remembered, with the next dose following the original schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Desmark

Evidence for use in Allergic Rhinitis

The research that explored Desmark's use in allergic rhinitis, which includes both seasonal and perennial forms, has primarily involved short-term randomized controlled trials (RCTs) and subsequent meta-analyses. These studies were used in research exploring how symptoms change over a defined time interval. Researchers have explored patterns observed in studies related to the measurement of Total Symptom Scores (TSS), which is a composite measure capturing symptoms like sneezing, nasal itching, congestion, and watery eyes.

Short-term studies described the symptom patterns that were observed in the populations when Desmark was compared to a placebo. Research also examined changes in objective measures such as nasal airflow and patient assessments of their Quality of Life (QoL), which reflect daily functioning or activity level. The findings reflect the specific populations and comparators evaluated in those trials.

Evidence for use in Chronic Idiopathic Urticaria (Chronic Hives)

The research for chronic idiopathic urticaria (CIU) was primarily studied in randomized, placebo-controlled trials. These studies were applied in research contexts involving fluctuating or unstable symptoms, where Desmark was studied for outcomes capturing phases of heightened symptom activity. The main outcome monitored was the severity of the condition, typically measured by the Urticaria Activity Score (UAS), which assesses the intensity of pruritus (itching) and the characteristics (number and size) of wheals (hives).

The evidence describes patterns of observed symptoms and related systemic or functional measures within these controlled study environments. Studies also monitored patient-reported outcomes, which included measures of perceived discomfort and functional limitations using Quality of Life (QoL) instruments. The results apply only to the specific populations studied.

Research Gaps and Areas of Uncertainty

A primary limitation in the evidence landscape is the duration of follow-up. Long-term effects are not fully established, meaning the evidence contributes to understanding symptom patterns but provides limited insight into long-term outcomes related to sustained control or disease management over many years. Furthermore, comparative evidence is lacking, as there are limited head-to-head trials that have evaluated Desmark against all other currently available second-generation antihistamines.

Key Studies & References

  1. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials

Frequently Asked Questions (FAQ)

Common questions about Desmark (FAQ)

Q: Do I have to take this medicine with food?

Official regulatory documents indicate that Desmark is recommended to be taken with a meal. Following the instructions regarding food intake helps ensure the medication is used as intended by the manufacturer.

Q: Does this medication make you feel dizzy?

Based on the official product information, dizziness has been reported as an uncommon side effect in clinical trials, meaning it may affect up to 1 in 100 people. If side effects such as dizziness occur, patients should exercise caution regarding activities requiring focus, such as driving or operating machinery.

Q: Can children use this medicine?

Regulatory documents specify that Desmark is not authorized or labelled for use in patients under 18 years of age. Decisions regarding off-label use in pediatric patients are clinical matters and are not detailed in the official product information.

How should Desmark be stored and disposed of?

How to Store and Dispose of Desmark?

The official regulatory instructions specify mandatory conditions for the storage and disposal of Desmark (Desloratadine) to maintain product quality and environmental safety.

Storage and Disposal Rule Regulatory Requirement
Temperature Range Store the medicine at or below 30 C (86 F).
Environmental Protection Keep the product in its original package to protect from moisture and keep from freezing.
Child Safety Keep out of the sight and reach of children (mandatory instruction).
Disposal Instructions Do not throw away unused or expired medicine via wastewater or household waste. Consult a pharmacist for proper disposal methods, which helps protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Desmark found in:

A-Z Index: